**SUPPLEMENTARY DATA**

**Supplementary Table S1. *ABCG2* allelic variants identified in the gout cohort and the normouricemic control group**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference SNP number** | **gout patients (N = 145)** | | | | | | **assuming codominance** | | **normouricemics** | | | | **p-value**  **gout vs. normo-uricemia** |
| **(N = 115)** | | | |
| **WW** | **WM** | **MM** | **W** | **M** | **p-value HWE** | **p-value**  **S-UA on treatment** | **p-value**  **S-UA off treatment** | **WW** | **WM** | **MM** | **M** |  |
| rs2231137 | 138 | 7 | 0 | 0.98 | 0.02 | 0.766 | 0.074 | 0.087 | 97 | 3 | 0 | 0.02 | 0.588 |
| rs369630458 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | monom.a | NS | NS | NS | NS | NS |
| rs4148152 | 138 | 7 | 0 | 0.98 | 0.02 | 0.766 | 0.074 | 0.087 | NS | NS | NS | NS | NS |
| rs2231138 | 139 | 6 | 0 | 0.98 | 0.02 | 0.799 | **0.038** | 0.093 | NS | NS | NS | NS | NS |
| rs5860119 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.97 | monom. | NS | NS | NS | NS | NS |
| rs3219193 | 145 | 0 | 0 | 1 | 0 | NS | monom. | NS | NS | NS | NS | NS | NS |
| rs2231142 | 84 | 55 | 6 | 0.77 | 0.23 | 0.416 | 0.835 | 0.471 | 86 | 13 | 1 | 0.08 | **0** |
| rs372192400 | 144 | 1 | 0 | 1 | 0 | 0.967 | monom. | 0.822 | 94 | 1 | 0 | 0.01 | 0.509 |
| rs753759474 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | monom. | 90 | 0 | 0 | 0 | 1 |
| rs2231144 | 142 | 3 | 0 | 0.99 | 0.01 | 0.9 | 0.883 | 0.822 | NS | NS | NS | NS | NS |
| rs757389397 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | 0.822 | NS | NS | NS | NS | NS |
| rs529343441 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | 0.822 | NS | NS | NS | NS | NS |
| rs753256449 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | monom. | NS | NS | NS | NS | NS |
| rs185332632 | 145 | 0 | 0 | 1 | 0 | NS | monom. | NS | NS | NS | NS | NS | NS |
| rs35622453 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | 0.822 | NS | NS | NS | NS | NS |
| rs752626614 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.97 | monom. | NS | NS | NS | NS | NS |
| rs2231148 | 84 | 49 | 12 | 0.75 | 0.25 | 0.215 | 0.437 | 0.954 | NS | NS | NS | NS | NS |
| rs769734146 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | 0.822 | 74 | 0 | 0 | 0 | 1 |
| rs2231153 | 0 | 8 | 137 | 0.03 | 0.97 | 0.733 | 0.334 | 0.417 | NS | NS | NS | NS | NS |
| rs2231156 | 99 | 45 | 1 | 0.84 | 0.16 | 0.086 | 0.425 | **0.041** | NS | NS | NS | NS | NS |
| rs2231155 | 142 | 3 | 0 | 0.99 | 0.01 | 0.9 | 0.967 | 0.974 | NS | NS | NS | NS | NS |
| rs199473697 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.612 | 0.822 | NS | NS | NS | NS | NS |
| rs6413443 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.97 | 1 | NS | NS | NS | NS | NS |
| rs2231157 | 69 | 57 | 19 | 0.67 | 0.33 | 0.195 | 0.587 | 0.282 | NS | NS | NS | NS | NS |
| rs2231162 | 5 | 8 | 132 | 0.06 | 0.94 | 0 | 0.278 | 0.207 | NS | NS | NS | NS | NS |
| rs2231164 | 5 | 55 | 85 | 0.22 | 0.78 | 0.275 | 0.109 | 0.471 | NS | NS | NS | NS | NS |
| rs2231165 | 142 | 3 | 0 | 0.99 | 0.01 | 0.9 | **0.022** | **0.043** | NS | NS | NS | NS | NS |
| rs34783571 | 143 | 2 | 0 | 0.99 | 0.01 | 0.933 | 0.675 | 0.822 | 95 | 0 | 0 | 0 | 0.5 |
| rs750972998 | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.97 | monom. | NS | NS | NS | NS | NS |
| p.Ser476Pro | 144 | 1 | 0 | 1 | 0 | 0.967 | 0.97 | 0.822 | NS | NS | NS | NS | NS |
| rs199854112 | 145 | 0 | 0 | 1 | 0 | NS | monom. | NS | NS | NS | NS | NS | NS |

Genotype distribution is given in absolute numbers, wild-type (W) and mutant (M) allele frequencies in relative numbers. aWhile some loci were not monomorphic over the whole set, the one bearer of the allelic variant was excluded from the association analysis because of missing SUA data. \*p-values for associations of allelic variants with SUA on and off treatment come from linear regression co-dominant model, p-values for associations of allelic variants with gout patient/normouricemic control status come from logistic regression co-dominant model. p-values < 0.05 are printed in bold. HWE: Hardy-Weinberg Equilibrium; SUA: serum uric acid; SNP: single nucleotide polymorphism.